Drug application
SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE (SODIUM SULFATE, MAGNESIUM SULFATE, UNSPECIFIED FORM, POTASSIUM CHLORIDE)
Drugs@FDA ANDA 220421 · HETERO LABS LIMITED, VEMAGAL
Key facts
| Drug name | SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE |
|---|---|
| Active ingredients | SODIUM SULFATE, MAGNESIUM SULFATE, UNSPECIFIED FORM, POTASSIUM CHLORIDE |
| Application type | ANDA |
| Application number | 220421 |
| Company | HETERO LABS LIMITED, VEMAGAL |
| Dosage forms | TABLET |
| Strength | 1.479G, 0.225G, 0.188G |
| Marketing status | None (Tentative Approval) |
| Reference listed drug | No |
| Latest submission status date | May 1, 2026 |
At a glance
- 1–9 Submissions
- None Label versions
- None Products
- None Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.